Effect of HIV Infection Status and Anti-retroviral Treatment on Quantitative and Qualitative Antibody Responses to Pneumococcal Conjugate Vaccine in Infants

Overview

Journal J Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2010 Jun 30

PMID 20583920

Citations 55

Authors

Shabir A Madhi

Peter Adrian

Mark F Cotton

James A McIntyre

Patrick Jean-Philippe

Shawn Meadows

Sharon Nachman

Helena Kayhty

Keith P Klugman

Avye Violari

Affiliations

Soon will be listed here.

Abstract

Serotype-specific antibody concentration and opsonophagocytic activity (OPA) were evaluated after 3 doses of pneumococcal conjugate vaccine. Groups included human immunodeficiency virus (HIV)-positive infants with CD4(+) cell percentages > or =25% who initiated immediate antiretroviral treatment (the HIV+/ART+ group) or whose antiretroviral treatment was deferred until clinically or immunologically indicated (the HIV+/ART- group). Immune responses were also evaluated in HIV-noninfected infants born to HIV-seronegative (M-/I-) or HIV-positive mothers (M+/I-). Antibody concentrations were similar between HIV+/ART+ and HIV+/ART- infants. However, antibody concentrations were lower in M-/I- infants than in M+/I- infants. Nevertheless, M-/I- infants had superior OPA responses, compared with those in HIV+/ART+ infants, who in turn had better OPA responses, compared with those in HIV+/ART- infants.

Citing Articles

Maternal immunity shapes biomarkers of germinal center development in HIV-exposed uninfected infants.

Yin L, Venturi G, Barfield R, Fischer B, Kim-Chang J, Chan C Front Immunol. 2024; 15:1443886.

PMID: 39328414 PMC: 11424517. DOI: 10.3389/fimmu.2024.1443886.

A narrative review of genomic characteristics, serotype, immunogenicity, and vaccine development of capsular polysaccharide.

Sari R, Fadilah F, Maladan Y, Sarassari R, Safari D Clin Exp Vaccine Res. 2024; 13(2):91-104.

PMID: 38752009 PMC: 11091432. DOI: 10.7774/cevr.2024.13.2.91.

Reduced white matter maturation in the central auditory system of children living with HIV.

Madzime J, Jankiewicz M, Meintjes E, Torre 3rd P, Laughton B, van der Kouwe A Front Neuroimaging. 2024; 3:1341607.

PMID: 38510428 PMC: 10951401. DOI: 10.3389/fnimg.2024.1341607.

Rates of Seroprotection against Vaccine-Preventable Infectious Diseases in HIV-Exposed and -Unexposed Malawian Infants.

Baroncelli S, Galluzzo C, Orlando S, Pirillo M, Luhanga R, Mphwere R Pathogens. 2023; 12(7).

PMID: 37513785 PMC: 10383556. DOI: 10.3390/pathogens12070938.

Nwosu E, Holmes M, Cotton M, Dobbels E, Little F, Laughton B BMC Neurosci. 2023; 24(1):15.

PMID: 36829110 PMC: 9951512. DOI: 10.1186/s12868-023-00783-7.

References

Clerici M, Saresella M, Colombo F, Fossati S, Sala N, Bricalli D . T-lymphocyte maturation abnormalities in uninfected newborns and children with vertical exposure to HIV. Blood. 2000; 96(12):3866-71. View

King Jr J, Vink P, Farley J, Smilie M, Parks M, Lichenstein R . Safety and immunogenicity of three doses of a five-valent pneumococcal conjugate vaccine in children younger than two years with and without human immunodeficiency virus infection. Pediatrics. 1997; 99(4):575-80. DOI: 10.1542/peds.99.4.575. View

Violari A, Cotton M, Gibb D, Babiker A, Steyn J, Madhi S . Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med. 2008; 359(21):2233-44. PMC: 2950021. DOI: 10.1056/NEJMoa0800971. View

Mansoor N, Scriba T, de Kock M, Tameris M, Abel B, Keyser A . HIV-1 infection in infants severely impairs the immune response induced by Bacille Calmette-Guérin vaccine. J Infect Dis. 2009; 199(7):982-90. PMC: 2815505. DOI: 10.1086/597304. View

Romero-Steiner S, Libutti D, Pais L, Dykes J, Anderson P, Whitin J . Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Clin Diagn Lab Immunol. 1997; 4(4):415-22. PMC: 170543. DOI: 10.1128/cdli.4.4.415-422.1997. View

Van Rie A, Madhi S, Heera J, Meddows-Taylor S, Wendelboe A, Anthony F . Gamma interferon production in response to Mycobacterium bovis BCG and Mycobacterium tuberculosis antigens in infants born to human immunodeficiency virus-infected mothers. Clin Vaccine Immunol. 2006; 13(2):246-52. PMC: 1391928. DOI: 10.1128/CVI.13.2.246-252.2006. View

Madhi S, Klugman K, Kuwanda L, Cutland C, Kayhty H, Adrian P . Quantitative and qualitative anamnestic immune responses to pneumococcal conjugate vaccine in HIV-infected and HIV-uninfected children 5 years after vaccination. J Infect Dis. 2009; 199(8):1168-76. DOI: 10.1086/597388. View

Nachman S, Kim S, King J, Abrams E, Margolis D, Petru A . Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants with human immunodeficiency virus type 1 infection. Pediatrics. 2003; 112(1 Pt 1):66-73. DOI: 10.1542/peds.112.1.66. View

Madhi S, Kuwanda L, Cutland C, Holm A, Kayhty H, Klugman K . Quantitative and qualitative antibody response to pneumococcal conjugate vaccine among African human immunodeficiency virus-infected and uninfected children. Pediatr Infect Dis J. 2005; 24(5):410-6. DOI: 10.1097/01.inf.0000160942.84169.14. View

10.

Newell M, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, Dabis F . Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet. 2004; 364(9441):1236-43. DOI: 10.1016/S0140-6736(04)17140-7. View

11.

Dagan R, Givon-Lavi N, Greenberg D, Fritzell B, Siegrist C . Nasopharyngeal carriage of Streptococcus pneumoniae shortly before vaccination with a pneumococcal conjugate vaccine causes serotype-specific hyporesponsiveness in early infancy. J Infect Dis. 2010; 201(10):1570-9. DOI: 10.1086/652006. View

12.

. Scaling up antiretroviral therapy in resource-limited settings: guidelines for a public health approach. Executive summary. April 2002. IAPAC Mon. 2002; 8(6):168-75. View

13.

Plikaytis B, Goldblatt D, Frasch C, Blondeau C, Bybel M, Giebink G . An analytical model applied to a multicenter pneumococcal enzyme-linked immunosorbent assay study. J Clin Microbiol. 2000; 38(6):2043-50. PMC: 86724. DOI: 10.1128/JCM.38.6.2043-2050.2000. View

14.

Siber G, Chang I, Baker S, Fernsten P, OBrien K, Santosham M . Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine. 2007; 25(19):3816-26. DOI: 10.1016/j.vaccine.2007.01.119. View